Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements
-
SFWJ / Medcana Announces Strategic Expansion Into Australia With Acquisition of Cannabis Import and Distribution Licenses
-
Spurs players 'never lost belief', says Postecoglou
-
Man Utd stun Lyon in nine-goal Europa League classic to reach semis
-
Netflix earnings in first quarter of 2025 top forecasts
-
Trump says US 'talking' to China on tariffs
-
Salvadoran soldiers stop US senator near prison holding expelled migrant
-
Solanke penalty sends Spurs to Europa League semis
-
CAF crackdown after trouble in African club matches
-
Trump talks up EU tariff deal as Italy's Meloni visits
-
Trump insists he could fire independent Fed Chair Powell
-
Google has illegal monopoly in ad tech, US judge rules
-
Trump softens on Zelensky, says mineral deal coming 'soon'
-
Jacks helps Mumbai beat Hyderabad in IPL
-
Countries must 'make the best' of new multipolar world: IMF chief
-
Heavy spring snow storm wreaks havoc in the Alps
-
US judge rules against Google in online ad tech antitrust case
-
Andreeva knocked out by Alexandrova in Stuttgart last 16
-
Iran challenges four countries in UN court over jet it downed in 2020
-
'Not at 50' - Alonso sets retirement limit
-
Macron praises US-European-Ukraine talks as 'important occasion for convergence'
-
Verstappen dismisses Red Bull exit fears
-
Italy's Meloni, Trump talk up EU trade deal hopes
-
'Slow but steady' progress for Martin after Qatar MotoGP crash
-
Pogacar-Van der Poel duel inspires Evenepoel comeback
-
US judge rules Google monopolized online ad tech market
-
Bearman back at 'special' debut-track Jeddah
-
Swiss watch exports to US soared ahead of Trump tariffs
-
Alcaraz finds best to reach Barcelona Open quarters
-
Where are all the aliens?: Fermi's Paradox explained
-
France full-back Dulin to retire at end of season
-
World economy likely to avoid recession despite tariffs: IMF chief
-
57 killed in Sudan's Darfur as trapped civilians fear bloodbath
-
Vietnam ups wind, solar targets as energy demand soars
-
Pope says doing 'best he can' on jail visit before Easter
-
China's Xi meets Cambodian leader as part of regional diplomatic blitz
-
Ukrainian tennis player seeks legal justice over 'moral abuse'
-
Italy's Meloni seeks EU tariff deal from Trump
-
France's feminist icon Pelicot to sue Paris Match for privacy invasion
-
World economy should avoid recession despite tariffs, IMF chief says
-
Stocks waver as ECB cuts rate, Trump slams Fed chief
-
France, UK mull migrant swaps in bid to stem Channel crossings
-
Nuno says Forest still in control of Champions League chase
-
Malinin, Liu help US take early lead at skating's World Team Trophy
-
Clashes in Sudan's besieged Darfur city kill 57
-
Kyiv's Europe allies seek influence with US in Paris talks
-
Russia scraps Taliban's 'terror' label amid warming ties
-
Trump says Fed chief's 'termination cannot come fast enough'
-
China's Xi, seeking to build regional ties, meets Cambodian leader
-
ECB cuts rates as Trump tariffs raise fears for eurozone growth
-
Etzebeth returns to Sharks lineup after concussion absence
Bionoid Pharma Inc. Engages Aloba, Awomolo & Partners as External Auditor for 2024 Financial Statements
NEW YORK, NY / ACCESS Newswire / April 9, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) today announced it has engaged Aloba, Awomolo & Partners, a PCAOB-registered accounting firm, as its independent external auditor for the fiscal year ended December 31, 2024.
This engagement underscores Bionoid's commitment to robust financial governance and transparency, aligning with its strategic initiatives to enhance market presence and shareholder value.
"We are pleased to welcome Aloba, Awomolo & Partners as our auditors for the 2024 fiscal year," said a spokesperson for Bionoid Pharma Inc. "Their expertise will be instrumental as we advance our financial reporting standards. Following our recent application to uplist to the OTCQB Venture Market, this audit represents a critical step toward achieving a more senior listing and reflects our dedication to providing investors with increased visibility and liquidity."
About Bionoid Pharma Inc.
Bionoid Pharma Inc. is a forward-thinking company focused on leveraging artificial intelligence to unlock new commercial opportunities and improve digital engagement. With a strategic emphasis on growth through acquisitions, Bionoid's five-year roadmap includes acquiring revenue-generating businesses and integrating its proprietary AI Maverick technology to enhance operational efficiency and user experience.
AI Maverick is a versatile, AI-powered platform designed to support a wide range of applications, from intelligent customer interaction tools to dynamic communication and data-driven engagement systems. As Bionoid continues to evolve, the flexibility of the Maverick platform provides a foundation for innovation across multiple sectors. Through these initiatives, the company aims to build long-term value, attract strategic partners, and establish a strong position in the rapidly expanding AI ecosystem.
Stay Connected:
Website: https://bionoidpharma.com
https://aimaverickintel.com/
OTC Markets: BINP
X (formerly Twitter): @BionoidPharminc
For Investor and Media Inquiries:
Wayne Cockburn, CEO
(905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
A.Malone--AMWN
